Dyadic International Inc, EnGen Bio, Sanofi deal

Dyadic's Dyadic Nederland B.V. subsidiary and EnGen partnered with the Sanofi Pasteur S.A. vaccines unit of Sanofi (formerly sanofi-aventis Group) to develop Dyadic's preclinical C1 fungal expression technology for vaccine indications. Sanofi Pasteur is responsible for development after Dyadic Nederland conducts proof-of-concept. Dyadic will receive undisclosed research fees from Sanofi Pasteur. Further terms were not disclosed. ...